Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Draft Criteria for ANCA-Associated Vasculitis Released

Susan Bernstein  |  Issue: March 2017  |  March 20, 2017

WASHINGTON, D.C.—Rheumatologists do not have up-to-date diagnostic and classification criteria for vasculitis, a group of diseases that involves inflammation of the blood vessels, said experts speaking at the 2016 ACR/ARHP Annual Meeting session, Classification Criteria for ANCA-Associated Vasculitis. The most recent classification criteria were published by the ACR in 1990, and since then, new disease definitions and diagnostic tests have changed the way the vasculitides are diagnosed and treated.1

“Microscopic polyangiitis [MPA] was not even a recognized entity in the 1980s, when the last classification criteria were developed, so it was missing from the 1990 ACR criteria,” said Ravi Suppiah, MBChB, MD, FRACP, one of the lead investigators of a new study to develop updated vasculitis criteria and a rheumatologist at the Auckland District Health Board in New Zealand. “Most patients who were included in the original ACR classification criteria who had, or [who] we would think of now as having, MPA, were classified as having polyarteritis nodosa.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

To address this need, a multiyear project was undertaken to develop new classification and diagnostic criteria that incorporate current disease definitions, medical technologies and therapies. The ongoing study, called the Diagnostic and Classification Criteria in Vasculitis Study (DCVAS), includes data on more than 6,300 vasculitis patients from more than 100 sites worldwide, and recruitment will continue through June 2017. Because of their interest in supporting classification criteria development, the ACR and the European League Against Rheumatism (EULAR) have contributed funding to the project.

During the session, lead investigators of the study presented a draft of classification criteria for GPA, the first set the study has produced. Classification criteria for MPA, eosinophilic granulomatosis with polyangiitis (EGPA) and ANCA-associated vasculitis (AAV) will be released shortly.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“Why do we need new criteria? The 1990 ACR criteria no longer fit the purpose,” said Dr. Suppiah. “They don’t correlate and are not consistent with our current definitions of these disease conditions,” he added, referring to the Chapel Hill Consensus conference definitions for vasculitis created in 2012.2 “Widely used tests for anti-neutrophil cytoplasmic antibodies (ANCA) and imaging techniques like computed tomography were not routinely available in clinical practice in the 1980s. Basically, it’s time for an update.”

‘Why do we need new criteria? The 1990 ACR criteria no longer fit the purpose. They don’t correlate & are not consistent with our current definitions of these disease conditions. It’s time for an update.’ —Dr. Suppiah

Classification criteria are used for research, not diagnosis, said co-investigator Peter Grayson, MD, PhD, head of the Vasculitis Translational Research Program at the National Institute of Arthritis and Musculoskeletal and Skin Diseases in Bethesda, Md.

Page: 1 2 3 | Single Page
Share: 

Filed under:ConditionsMeeting ReportsVasculitis Tagged with:2016 ACR/ARHP Annual MeetingAmerican College of Rheumatology (ACR)ANCAcriteriaDiagnosisDiagnostic and Classification Criteria in Vasculitis Studyrheumatologistupdate

Related Articles
    Figure 2: Renal Biopsy

    The Classification & Diagnosis of Granulomatosis with Polyangiitis

    August 16, 2018

    Based on the classification system developed by the Chapel Hill Consensus Conference, anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis is defined as a necrotizing vasculitis involving small vessels that is associated with myeloperoxidase (MPO) ANCA or proteinase 3 (PR3) ANCA and displays minimal immune deposits. The mechanism behind the pathogenesis of ANCA-associated vasculitis is not fully…

    Figure 1. A nasal biopsy shows intimal infiltration of the small blood vessels (black arrow).

    Case Illustrates the Difficulty Diagnosing Granulomatosis with Polyangiitis

    June 21, 2018

    Granulomatosis with polyangiitis (GPA) was first described in the British Medical Journal in 1897 by Scottish otolaryngologist Peter McBride.1 GPA is a relatively rare, systemic necrotizing vasculitis that can make diagnosis challenging. The incidence has been estimated anywhere between two and 12 cases per million.2 GPA mainly affects adults between the ages of 45 and…

    Case Report: Hydralazine-Induced ANCA-Associated Vasculitis

    February 16, 2021

    Hydralazine has been in use as a treatment for hypertension, most notably in heart failure patients, since 1951.1 The drug is a known cause of autoimmune disease, most specifically hydralazine-induced lupus.  Hydralazine-induced lupus occurs in 7–13% of those taking the medication.2-4 It often presents with constitutional symptoms, arthritis/arthralgias, cutaneous lesions, sero­sitis, myalgias and/or hepatomegaly. Features…

    Research Offers Insight into Diagnosis, Treatment of Small-Vessel Vasculitis

    March 20, 2017

    WASHINGTON, D.C.—Experts speaking at the 2016 ACR/ARHP Annual Meeting session, Update on Small-Vessel Vasculitis, offered insight into the latest approaches to the diagnosis and treatment of diseases involving the inflammation of blood vessels. “Vasculitis is an immune-mediated process. White blood cells invade the vessel wall, causing inflammation throughout the vessel wall,” said Jason M. Springer,…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences